Clinical trials: H Pylori Eradication
H. Pylori Infection
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and…
- Trial name
- NCT01505127
- Testing
- TAK-438, Lansoprazole, Amoxicillin
- Where
- 35 sites in Japan
- Volunteers
- 650 people
- Sponsor
- Takeda
Duodenal Ulcer
Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers
The Study purpose is to evaluate Helicobacter pylori susceptibility to Clarithromycin and to estimate eradication and healing rates of duodenal ulcer routine eradication therapy at the end of treatment and 52 weeks from the…
- Trial name
- NCT01199536
- Where
- Russia
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
H Pylori Gastritis, H Pylori Infection
Efficacy of Carminal in Helicobacter Pylori Gastritis
Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be…
- Conditions
- H Pylori Gastritis, H Pylori Infection, H Pylori Eradication, Gastritis Associated With Helicobacter Pylori
- Trial name
- NCT07179237
- Testing
- Carminal Oral solution
- Where
- 2 sites in Serbia
- Volunteers
- 80 people
- Sponsor
- Catalysis SL
Stomach Ulcer
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
- Trial name
- NCT00272467
- Testing
- Rebamipide, Omeprazole
- Where
- 7 sites in China, South Korea
- Volunteers
- 132 people
- Sponsor
- Korea Otsuka International Asia Arab
Helicobacter Infections
Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
This study compared efficacy and safety of basic triple therapy including Ilaprazole 10mg, Levofloxacin 500mg and Amoxicillin 1000mg BID for 10 days on the first line eradication treatment of H.pylori
- Trial name
- NCT02352701
- Testing
- Noltec tab. 10mg, Chongkundang Amoxicillin Cap. 500mg, Cravit Tab. 500mg
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Helicobacter Pylori Infection
A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy
- Trial name
- NCT03099876
- Testing
- treatment period
- Where
- 4 sites in South Korea
- Volunteers
- 320 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM)…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Gastric Mucosa-associated Lymphoid Tissue (MALT), Lymphoma Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT01435525
- Where
- 36 sites in Japan
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Helicobacter pylori (H. pylori) infection is highly associated with gastrointestinal disorders, including peptic ulcer disease, gastric cancer, and gastric mucosa associated lymphoid tissue lymphoma.1 In 1994, H.
- Trial name
- NCT02959255
- Testing
- Esomeprazole
- Where
- Greece
- Volunteers
- 364 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Helicobacter Pylori Infection
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
This study is a multicenter, randomized, double-blind, double-dummy, phase III study to evaluate the efficacy and safety of tegoprazan versus esomeprazole-containing bismuth quadruple therapy in patients infected with…
- Trial name
- NCT05577468
- Testing
- Tegoprazan
- Where
- China
- Volunteers
- 561 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
- Trial name
- NCT01264822
- Testing
- Rabeprazole Sodium
- Where
- 42 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Eisai Co., Ltd.
Helicobacter Pylori Infection
Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %.
- Trial name
- NCT01131026
- Testing
- Levofloxacin, Amoxicillin, Lansoprazole
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Deva Holding A.S.
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
- Trial name
- NCT03219723
- Testing
- Vonoprazan, Amoxicillin hydrate, Clarithromycin
- Where
- Japan
- Volunteers
- 560 people
- Sponsor
- Takeda
Helicobacter Pylori Infection, Gastrointestinal Dysbiosis
Bacillus Probiotics With Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is a very common gastrointestinal disease that colonises the human gastric mucosa and is a primary risk factor for chronic gastritis, peptic ulcer disease, and gastric cancer.
- Conditions
- Helicobacter Pylori Infection, Gastrointestinal Dysbiosis, Antibiotic-associated Adverse Events
- Trial name
- NCT07827170
- Testing
- RO water, LiveSpo CLAUSY, LiveSpo DIA30
- Where
- Vietnam
- Volunteers
- 336 people
- Sponsor
- Anabio R&D
Helicobacter Pylori Infection
Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
The purpose of the study is assess whether the various forms of triple regimen of administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and any independent mealtime) influence the rate of…
- Trial name
- NCT02552641
- Testing
- Food effect, Esomeprazole, Amoxicillin
- Where
- Brazil
- Sponsor
- EMS
Helicobacter Pylori
Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication
The goal of this prospective randomized clinical trial is to compare the rate of Helicobacter Pylori (HP) eradication after standard or dose-optimized amoxicillin quadritherapy in patients naïve to any anti-HP treatment and with…
- Trial name
- Helicomatri (NCT05635942)
- Testing
- optimized quadruple therapy, standard quadruple therapy
- Where
- Tunisia
- Volunteers
- 88 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Peptic Ulcer
Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment
The purpose of this study is to evaluate of efficacy and safety as H.pylori eradiation effect between Ilaprazole and Pantoprazole triple therapy for 7 days treatment in Gastric and/or Duodenal ulcer patients with H.pylori…
- Trial name
- NCT02084420
- Testing
- Ilaprazole, Pantoprazole
- Where
- 18 sites in South Korea
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Helicobacter Pylori Infection
Efficacy and Safety of Lacidofil® STRONG as an Adjuvant for Helicobacter Pylori Treatment in Non-ulcer Dyspepsia
Treatment for H. pylori eradication includes antibiotics. The treatment has decreased its efficiency (lower capability to eradicate the infection) due to increasing antibiotic resistance in the population.
- Trial name
- NCT04473079
- Testing
- Lacidofil
- Where
- Thailand
- Volunteers
- 90 people
- Sponsor
- Lallemand Health Solutions
Helicobacter Pylori Eradication
Effect of Probiotics on Helicobacter Pylori Eradication
The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions of Helicobacter pylori quadruple…
- Trial name
- NCT04034641
- Testing
- Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy
- Where
- 2 sites in China
- Volunteers
- 238 people
- Sponsor
- Hangzhou Grand Biologic Pharmaceutical, Inc.
Helicobacter Pylori
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
The main aim of the study is to review treatment therapies in people with Helicobacter pylori (H. pylori) infections in standard hospital settings in China.
- Trial name
- NCT05073367
- Where
- 5 sites in China
- Volunteers
- 23,000 people
- Sponsor
- Takeda
Helicobacter Pylori Gastritis
Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.
The goal of this trial is to compare the non-inferiority efficacy and safety of two different treatment schemes: pantoprazole 80 mg + levofloxacin 500 mg + azithromycin 500 mg once daily (PLA, test) vs.
- Trial name
- NCT02726269
- Testing
- CLA (Clarithro+Lanso+Amoxi), PLA (Panto+Levoflox+Azithro)
- Volunteers
- 230 people
- Sponsor
- Asofarma de México S.A de C.V.